All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

cefepime 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, cefalosporanic acid derivatives	535	88040-23-7

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: cefepime dihydrochloride hydrate cefepime cefepime hydrochloride cefimen tsefepim cefepime HCl

A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA. Molecular weight: 480.56 Formula: C19H24N6O5S2 CLOGP: -4.87 LIPINSKI: 1 HAC: 11 HDO: 2 TPSA: 150.04 ALOGS: -4.49 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
4	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	85 %	Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.28 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2.20 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.78 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.90 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 18, 1996	FDA	HOSPIRA INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Encephalopathy	369.76	18.17	183	14009	33528	50557404
Acute kidney injury	296.41	18.17	341	13851	227717	50363215
Febrile neutropenia	262.88	18.17	218	13974	97449	50493483
Neurotoxicity	188.57	18.17	89	14103	14651	50576281
Status epilepticus	177.83	18.17	83	14109	13323	50577609
Sepsis	141.42	18.17	180	14012	132745	50458187
Myoclonus	136.42	18.17	71	14121	14399	50576533
Drug reaction with eosinophilia and systemic symptoms	136.37	18.17	90	14102	28334	50562598
Cytokine release syndrome	131.93	18.17	59	14133	8575	50582357
Pyrexia	130.03	18.17	311	13881	379892	50211040
Multiple organ dysfunction syndrome	120.10	18.17	105	14087	50232	50540700
Septic shock	99.33	18.17	100	14092	57075	50533857
Thrombocytopenia	98.28	18.17	148	14044	127525	50463407
Tubulointerstitial nephritis	95.13	18.17	57	14135	15154	50575778
Toxic encephalopathy	88.47	18.17	39	14153	5476	50585456
Mental status changes	87.17	18.17	76	14116	36196	50554736
Respiratory failure	85.27	18.17	116	14076	91065	50499867
Pain	84.03	18.17	29	14163	578874	50012058
Clostridium difficile colitis	68.12	18.17	49	14143	17693	50573239
Pneumonia	66.79	18.17	245	13947	378156	50212776
Arthralgia	65.28	18.17	21	14171	438681	50152251
Klebsiella infection	64.09	18.17	34	14158	7160	50583772
Neutrophil count decreased	63.07	18.17	71	14121	45955	50544977
Fatigue	60.41	18.17	66	14126	707535	49883397
Platelet count decreased	60.00	18.17	104	14088	100622	50490310
Drug resistance	58.57	18.17	46	14146	18943	50571989
Renal tubular necrosis	58.17	18.17	36	14156	10132	50580800
Pathogen resistance	56.73	18.17	29	14163	5660	50585272
Neutropenia	55.70	18.17	126	14066	147839	50443093
Alopecia	53.50	18.17	4	14188	245043	50345889
Hypoxia	52.29	18.17	68	14124	51055	50539877
Acute generalised exanthematous pustulosis	49.50	18.17	31	14161	8907	50582025
Mixed liver injury	47.71	18.17	22	14170	3429	50587503
Abdominal discomfort	47.27	18.17	5	14187	231636	50359296
Cytomegalovirus test positive	47.03	18.17	20	14172	2572	50588360
Drug intolerance	46.64	18.17	4	14188	219100	50371832
Headache	44.52	18.17	46	14146	506489	50084443
Immune effector cell-associated neurotoxicity syndrome	42.93	18.17	15	14177	1135	50589797
Nasopharyngitis	42.52	18.17	3	14189	192924	50398008
Fungaemia	41.47	18.17	17	14175	1995	50588937
Bacteraemia	40.32	18.17	33	14159	14400	50576532
Rheumatoid arthritis	39.75	18.17	5	14187	202545	50388387
Aspartate aminotransferase increased	39.39	18.17	75	14117	77923	50513009
Malaise	38.87	18.17	23	14169	335509	50255423
Acute respiratory distress syndrome	38.62	18.17	38	14154	21061	50569871
Clostridium difficile infection	37.87	18.17	41	14151	25398	50565534
Nephropathy toxic	37.45	18.17	25	14167	8004	50582928
Renal impairment	36.06	18.17	71	14121	75590	50515342
Confusional state	35.75	18.17	124	14068	185804	50405128
Pancytopenia	35.49	18.17	75	14117	83955	50506977
Trichosporon infection	34.77	18.17	9	14183	241	50590691
Hypotension	34.52	18.17	144	14048	235325	50355607
Antibiotic level above therapeutic	34.42	18.17	9	14183	251	50590681
Respiratory distress	33.44	18.17	42	14150	30447	50560485
Nephritis allergic	33.42	18.17	8	14184	154	50590778
Dizziness	33.25	18.17	29	14163	346340	50244592
Shock	32	18.17	34	14158	20616	50570316
Renal failure	31.73	18.17	83	14109	106550	50484382
Toxic epidermal necrolysis	31.54	18.17	34	14158	20958	50569974
Metabolic encephalopathy	31.51	18.17	19	14173	5102	50585830
Hepatic function abnormal	31.14	18.17	42	14150	32639	50558293
Enterococcal infection	31.03	18.17	21	14171	6877	50584055
White blood cell count decreased	30.88	18.17	87	14105	116635	50474297
Enterococcal bacteraemia	30.68	18.17	12	14180	1246	50589686
Product dose omission issue	30.65	18.17	7	14185	183831	50407101
Differentiation syndrome	30.39	18.17	11	14181	922	50590010
Peripheral swelling	30.30	18.17	10	14182	205926	50385006
Dysbiosis	30.08	18.17	10	14182	650	50590282
Toxic skin eruption	29.92	18.17	25	14167	11226	50579706
Hypertensive heart disease	29.91	18.17	14	14178	2256	50588676
Alanine aminotransferase increased	29.66	18.17	72	14120	88287	50502645
Pseudomonas infection	29.41	18.17	23	14169	9407	50581525
Anaemia	29.22	18.17	144	14048	252312	50338620
Bronchopulmonary aspergillosis	29.21	18.17	21	14171	7571	50583361
Weight decreased	28.81	18.17	13	14179	221232	50369700
Blood creatinine increased	28.77	18.17	65	14127	76095	50514837
Mucormycosis	28.72	18.17	14	14178	2469	50588463
Leukocytosis	27.84	18.17	33	14159	22546	50568386
Therapeutic product effect decreased	27.57	18.17	3	14189	136047	50454885
Sinusitis	27.44	18.17	7	14185	170551	50420381
Acute respiratory failure	27.44	18.17	37	14155	28745	50562187
Klebsiella bacteraemia	27.03	18.17	11	14181	1266	50589666
Systemic lupus erythematosus	26.33	18.17	4	14188	140618	50450314
Acute graft versus host disease in skin	26.13	18.17	14	14178	3004	50587928
Eosinophilia	25.92	18.17	29	14163	18623	50572309
Graft versus host disease	25.91	18.17	18	14174	6148	50584784
Eosinophilic pneumonia	25.89	18.17	12	14180	1892	50589040
Swelling	25.85	18.17	12	14180	200860	50390072
Cholestatic liver injury	25.20	18.17	12	14180	2009	50588923
Rash maculo-papular	25.02	18.17	34	14158	26607	50564325
Hyperoxaluria	24.57	18.17	6	14186	126	50590806
Agranulocytosis	24.27	18.17	30	14162	21391	50569541
Stenotrophomonas infection	24.20	18.17	11	14181	1658	50589274
Chemotherapeutic drug level increased	24.17	18.17	6	14186	135	50590797
Leukopenia	23.70	18.17	56	14136	67472	50523460
Acute myeloid leukaemia	23.68	18.17	25	14167	15049	50575883
Aphasia	23.25	18.17	34	14158	28460	50562472
Hypersensitivity	23.17	18.17	16	14176	215145	50375787
Neutropenic colitis	23.17	18.17	12	14180	2405	50588527
Engraft failure	22.97	18.17	7	14185	343	50590589
Hyperbilirubinaemia	22.86	18.17	20	14172	9550	50581382
Cytomegalovirus viraemia	22.78	18.17	15	14177	4694	50586238
Gait disturbance	22.56	18.17	7	14185	149998	50440934
Cholestasis	21.73	18.17	31	14161	25370	50565562
Pseudomembranous colitis	21.57	18.17	12	14180	2773	50588159
Disseminated intravascular coagulation	21.05	18.17	25	14167	17110	50573822
Hypoaesthesia	20.90	18.17	5	14187	127252	50463680
Ileus	20.88	18.17	22	14170	13207	50577725
Fall	20.76	18.17	39	14153	334893	50256039
Enterococcal sepsis	20.39	18.17	9	14183	1266	50589666
Encephalitis Japanese B	20.29	18.17	4	14188	29	50590903
Respiratory alkalosis	19.91	18.17	11	14181	2508	50588424
Tonsillitis bacterial	19.84	18.17	5	14187	120	50590812
Laryngeal inflammation	19.38	18.17	5	14187	132	50590800
Musculoskeletal stiffness	19.31	18.17	6	14186	128475	50462457
Angiokeratoma	19.24	18.17	5	14187	136	50590796
Weight increased	19.22	18.17	17	14175	201874	50389058
Electrocardiogram T wave alternans	18.96	18.17	4	14188	42	50590890
Staphylococcal infection	18.90	18.17	35	14157	35581	50555351
Systemic candida	18.86	18.17	11	14181	2779	50588153
Lymphatic disorder	18.69	18.17	6	14186	349	50590583
Activated partial thromboplastin time prolonged	18.64	18.17	15	14177	6387	50584545
Muscle spasms	18.62	18.17	6	14186	125547	50465385
Mucosal inflammation	18.31	18.17	37	14155	40105	50550827
Thrombotic microangiopathy	18.30	18.17	17	14175	8774	50582158
Subdiaphragmatic abscess	18.25	18.17	4	14188	51	50590881

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Encephalopathy	230.30	16.18	176	18529	30867	29524955
Acute kidney injury	198.19	16.18	483	18222	264784	29291038
Febrile neutropenia	165.45	16.18	272	18433	111968	29443854
Neurotoxicity	149.99	16.18	101	18604	14512	29541310
Cytokine release syndrome	147.55	16.18	96	18609	13023	29542799
Septic shock	102.10	16.18	159	18546	62401	29493421
Drug reaction with eosinophilia and systemic symptoms	96.28	16.18	103	18602	27889	29527933
Multiple organ dysfunction syndrome	92.83	16.18	153	18552	62963	29492859
Respiratory failure	88.69	16.18	192	18513	96939	29458883
Pyrexia	83.65	16.18	381	18324	287241	29268581
Acute generalised exanthematous pustulosis	78.24	16.18	47	18658	5536	29550286
Fatigue	72.28	16.18	57	18648	316764	29239058
Tubulointerstitial nephritis	71.64	16.18	71	18634	17572	29538250
Hypoxia	71.17	16.18	116	18589	47263	29508559
Clostridium difficile colitis	70.69	16.18	62	18643	13150	29542672
Renal tubular necrosis	68.35	16.18	63	18642	14252	29541570
Sepsis	64.07	16.18	217	18488	142465	29413357
Myoclonus	62.43	16.18	58	18647	13251	29542571
Pathogen resistance	62.26	16.18	47	18658	8069	29547753
Neutrophil count decreased	57.89	16.18	101	18604	43466	29512356
Mental status changes	57.23	16.18	89	18616	34838	29520984
Methaemoglobinaemia	55.16	16.18	29	18676	2642	29553180
Neutropenia	52.79	16.18	193	18512	131518	29424304
Dizziness	51.46	16.18	28	18677	189656	29366166
Enterococcal infection	50.77	16.18	42	18663	8226	29547596
Product dose omission issue	49.02	16.18	3	18702	96380	29459442
Immune effector cell-associated neurotoxicity syndrome	47.79	16.18	22	18683	1502	29554320
Death	46.10	16.18	92	18613	341992	29213830
Brain herniation	44.32	16.18	28	18677	3605	29552217
Meningitis candida	42.79	16.18	10	18695	71	29555751
Disseminated intravascular coagulation	41.56	16.18	57	18648	19923	29535899
Nephropathy toxic	41.29	16.18	42	18663	10714	29545108
Status epilepticus	41.17	16.18	42	18663	10752	29545070
Haemodialysis	40.29	16.18	40	18665	9914	29545908
Myocardial infarction	38.53	16.18	11	18694	110285	29445537
Bacteraemia	36.13	16.18	48	18657	16275	29539547
Pseudomonas infection	35.65	16.18	39	18666	10813	29545009
Botulism	35.44	16.18	10	18695	160	29555662
Systemic candida	35.36	16.18	22	18683	2758	29553064
Platelet count decreased	35.05	16.18	145	18560	104527	29451295
Glomerulosclerosis	34.42	16.18	14	18691	706	29555116
Drug resistance	34.04	16.18	54	18651	21486	29534336
Blood culture positive	33.98	16.18	26	18679	4551	29551271
Thrombocytopenia	33.46	16.18	171	18534	134652	29421170
Fall	33.11	16.18	38	18667	177140	29378682
Antibiotic level above therapeutic	32.89	16.18	10	18695	210	29555612
Immune thrombocytopenia	32.52	16.18	32	18673	7845	29547977
Bronchopulmonary aspergillosis	31.57	16.18	39	18666	12305	29543517
Uraemic encephalopathy	30.69	16.18	10	18695	265	29555557
Clostridium difficile infection	30.52	16.18	44	18661	16097	29539725
Aspergillus infection	29.62	16.18	35	18670	10546	29545276
Confusional state	29.52	16.18	159	18546	127718	29428104
Cytomegalovirus enterocolitis	29.51	16.18	13	18692	800	29555022
Arthralgia	29.41	16.18	27	18678	139590	29416232
Depression	28.81	16.18	9	18696	85138	29470684
Disseminated mucormycosis	28.44	16.18	10	18695	336	29555486
White blood cell count decreased	28.30	16.18	116	18589	83246	29472576
Candida infection	28.06	16.18	41	18664	15184	29540638
Aspartate aminotransferase increased	27.75	16.18	92	18613	59633	29496189
Eosinophilia	27.64	16.18	50	18655	22111	29533711
Pleural effusion	27.59	16.18	104	18601	71804	29484018
Metabolic encephalopathy	27.50	16.18	21	18684	3666	29552156
Burkholderia test positive	26.95	16.18	13	18692	986	29554836
Cytomegalovirus viraemia	26.70	16.18	26	18679	6294	29549528
Malaise	25.93	16.18	38	18667	159564	29396258
Enterocolitis	25.53	16.18	26	18679	6640	29549182
Weight decreased	25.43	16.18	35	18670	150870	29404952
Acute respiratory distress syndrome	25.18	16.18	49	18656	22886	29532936
Klebsiella infection	25.17	16.18	27	18678	7322	29548500
Rash morbilliform	25.01	16.18	17	18688	2476	29553346
Acute myeloid leukaemia recurrent	24.97	16.18	15	18690	1765	29554057
Pain	24.86	16.18	44	18661	171388	29384434
Transaminases increased	24.38	16.18	48	18657	22614	29533208
Gait disturbance	24.37	16.18	8	18697	73341	29482481
Insomnia	24.17	16.18	13	18692	88748	29467074
Septic embolus	23.40	16.18	12	18693	1038	29554784
Toxic encephalopathy	23.38	16.18	21	18684	4591	29551231
Mucormycosis	23.26	16.18	22	18683	5136	29550686
Cholestasis	23.22	16.18	48	18657	23414	29532408
Respiratory distress	23.22	16.18	58	18647	32048	29523774
Bacterial toxaemia	23.07	16.18	7	18698	146	29555676
Choluria	23.02	16.18	7	18698	147	29555675
Cytokine storm	22.83	16.18	10	18695	607	29555215
Corynebacterium infection	22.73	16.18	9	18696	423	29555399
Trichosporon infection	22.48	16.18	10	18695	630	29555192
Alanine aminotransferase increased	21.96	16.18	96	18609	70848	29484974
Renal failure	21.86	16.18	139	18566	118460	29437362
Pneumonia bacterial	21.48	16.18	28	18677	9315	29546507
Joint swelling	21.37	16.18	3	18702	49627	29506195
Blood pressure increased	21.31	16.18	10	18695	73793	29482029
Fungal infection	21.19	16.18	34	18671	13651	29542171
Dyspnoea	21.08	16.18	121	18584	326611	29229211
Hypersensitivity vasculitis	20.95	16.18	17	18688	3240	29552582
Kidney fibrosis	20.63	16.18	14	18691	2033	29553789
Cerebral aspergillosis	20.52	16.18	12	18693	1344	29554478
Acute lymphocytic leukaemia recurrent	20.25	16.18	15	18690	2501	29553321
Vanishing bile duct syndrome	20.05	16.18	9	18696	579	29555243
Anxiety	19.82	16.18	15	18690	85350	29470472
Feeling abnormal	19.81	16.18	5	18700	54440	29501382
Hospitalisation	19.29	16.18	3	18702	45985	29509837
Headache	19.16	16.18	52	18653	173955	29381867
Blood creatinine increased	19.06	16.18	105	18600	84997	29470825
Toxic epidermal necrolysis	18.98	16.18	38	18667	18115	29537707
Aphasia	18.67	16.18	39	18666	19159	29536663
Drug intolerance	18.48	16.18	4	18701	48375	29507447
Inappropriate schedule of product administration	18.43	16.18	3	18702	44469	29511353
Procalcitonin increased	18.41	16.18	12	18693	1630	29554192
Systemic mycosis	18.19	16.18	11	18694	1310	29554512
Drug level increased	18.08	16.18	38	18667	18749	29537073
Eye infection fungal	17.90	16.18	7	18698	318	29555504
Peripheral swelling	17.84	16.18	9	18696	63730	29492092
Sputum culture positive	17.70	16.18	12	18693	1740	29554082
Retinal ischaemia	17.68	16.18	7	18698	329	29555493
Flavobacterium infection	17.66	16.18	5	18700	81	29555741
Hepatosplenic candidiasis	17.20	16.18	6	18699	197	29555625
Asthenia	17.13	16.18	74	18631	215176	29340646
Hypercapnia	17.01	16.18	16	18689	3710	29552112
Dysbiosis	16.53	16.18	7	18698	391	29555431
Liver abscess	16.53	16.18	15	18690	3323	29552499
Staphylococcal sepsis	16.52	16.18	24	18681	8838	29546984
Adenoviral haemorrhagic cystitis	16.45	16.18	7	18698	396	29555426
Gastrointestinal mucormycosis	16.27	16.18	5	18700	109	29555713

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Encephalopathy	536.77	16.12	340	30532	58479	64409381
Acute kidney injury	440.10	16.12	776	30096	448464	64019396
Febrile neutropenia	352.56	16.12	441	30431	187216	64280644
Neurotoxicity	318.19	16.12	185	30687	27219	64440641
Cytokine release syndrome	272.40	16.12	152	30720	20677	64447183
Drug reaction with eosinophilia and systemic symptoms	206.70	16.12	186	30686	54031	64413829
Status epilepticus	194.28	16.12	124	30748	21539	64446321
Septic shock	180.61	16.12	237	30635	105200	64362660
Myoclonus	175.25	16.12	123	30749	24995	64442865
Pyrexia	173.42	16.12	623	30249	558021	63909839
Multiple organ dysfunction syndrome	166.06	16.12	223	30649	101190	64366670
Sepsis	164.34	16.12	349	30523	229992	64237868
Tubulointerstitial nephritis	152.49	16.12	123	30749	30786	64437074
Respiratory failure	147.24	16.12	271	30601	160912	64306948
Mental status changes	139.60	16.12	159	30713	61003	64406857
Renal tubular necrosis	128.61	16.12	97	30775	22013	64445847
Thrombocytopenia	124.01	16.12	307	30565	223494	64244366
Fatigue	118.28	16.12	111	30761	748619	63719241
Neutrophil count decreased	114.65	16.12	162	30710	77034	64390826
Clostridium difficile colitis	112.88	16.12	98	30774	27125	64440735
Hypoxia	112.17	16.12	172	30700	87977	64379883
Pain	109.26	16.12	65	30807	553446	63914414
Platelet count decreased	100.25	16.12	237	30635	167474	64300386
Neutropenia	99.86	16.12	296	30576	239328	64228532
Arthralgia	99.02	16.12	44	30828	442216	64025644
Pathogen resistance	98.28	16.12	66	30806	12477	64455383
Drug resistance	93.50	16.12	99	30773	35003	64432857
Toxic encephalopathy	90.01	16.12	57	30815	9758	64458102
Dizziness	89.88	16.12	47	30825	430116	64037744
Immune effector cell-associated neurotoxicity syndrome	89.85	16.12	37	30835	2558	64465302
Joint swelling	83.12	16.12	5	30867	215377	64252483
Acute generalised exanthematous pustulosis	80.25	16.12	61	30811	13997	64453863
Enterococcal infection	78.79	16.12	60	30812	13806	64454054
Klebsiella infection	76.63	16.12	58	30814	13223	64454637
Headache	76.03	16.12	85	30787	529382	63938478
Nephropathy toxic	72.50	16.12	63	30809	17451	64450409
Product dose omission issue	70.88	16.12	6	30866	194741	64273119
Malaise	69.39	16.12	53	30819	396194	64071666
Pneumonia	65.68	16.12	475	30397	559101	63908759
Drug intolerance	65.22	16.12	7	30865	187985	64279875
Bacteraemia	63.13	16.12	71	30801	26840	64441020
Rheumatoid arthritis	59.95	16.12	5	30867	164289	64303571
Clostridium difficile infection	59.84	16.12	80	30792	36083	64431777
Disseminated intravascular coagulation	58.87	16.12	75	30797	32273	64435587
White blood cell count decreased	58.24	16.12	187	30685	157650	64310210
Confusional state	57.20	16.12	262	30610	260882	64206978
Renal failure	57.12	16.12	204	30668	181484	64286376
Antibiotic level above therapeutic	56.40	16.12	18	30854	595	64467265
Fall	55.42	16.12	71	30801	416755	64051105
Nasopharyngitis	55.26	16.12	13	30859	196060	64271800
Methaemoglobinaemia	54.83	16.12	31	30841	4317	64463543
Aspartate aminotransferase increased	54.66	16.12	153	30719	119635	64348225
Trichosporon infection	53.55	16.12	19	30853	873	64466987
Alopecia	53.04	16.12	8	30864	165682	64302178
Metabolic encephalopathy	52.95	16.12	38	30834	7987	64459873
Acute respiratory distress syndrome	52.36	16.12	78	30794	38857	64429003
Pseudomonas infection	52.22	16.12	53	30819	17830	64450030
Peripheral swelling	51.33	16.12	18	30854	209135	64258725
Bronchopulmonary aspergillosis	51.12	16.12	54	30818	19031	64448829
Haemodialysis	50.58	16.12	51	30821	17026	64450834
Pancytopenia	49.46	16.12	166	30706	143143	64324717
Mucormycosis	48.98	16.12	35	30837	7306	64460554
Eosinophilia	47.97	16.12	74	30798	38002	64429858
Brain herniation	47.90	16.12	33	30839	6500	64461360
Weight decreased	47.74	16.12	40	30832	285699	64182161
Blood creatinine increased	47.49	16.12	158	30714	135624	64332236
Arthropathy	46.07	16.12	3	30869	120964	64346896
Abdominal discomfort	44.21	16.12	16	30856	182306	64285554
Gait disturbance	43.66	16.12	14	30858	172141	64295719
Pleural effusion	43.13	16.12	146	30726	126413	64341447
Cholestasis	42.84	16.12	77	30795	44795	64423065
Respiratory distress	42.75	16.12	84	30788	52247	64415613
Toxic epidermal necrolysis	42.36	16.12	69	30803	37097	64430763
Alanine aminotransferase increased	41.89	16.12	154	30718	138877	64328983
Systemic candida	41.65	16.12	28	30844	5301	64462559
Dyspnoea	41.60	16.12	190	30682	718484	63749376
Myocardial infarction	41.15	16.12	14	30858	165807	64302053
Cytomegalovirus viraemia	40.93	16.12	37	30835	10791	64457069
Meningitis candida	39.98	16.12	10	30862	132	64467728
Fungaemia	39.83	16.12	24	30848	3761	64464099
Pain in extremity	38.84	16.12	53	30819	303032	64164828
Depression	38.24	16.12	20	30852	183271	64284589
Neutropenic colitis	38.05	16.12	25	30847	4556	64463304
Enterocolitis	37.64	16.12	37	30835	11981	64455879
Hypotension	36.05	16.12	308	30564	380666	64087194
Acute respiratory failure	35.86	16.12	76	30796	49858	64418002
Differentiation syndrome	35.32	16.12	18	30854	2036	64465824
Septic embolus	34.91	16.12	17	30855	1745	64466115
Agranulocytosis	34.47	16.12	64	30808	38165	64429695
Aphasia	33.82	16.12	66	30806	40840	64427020
Musculoskeletal stiffness	33.09	16.12	9	30863	123197	64344663
Blood pressure increased	32.90	16.12	21	30851	172531	64295329
Cholestatic liver injury	32.82	16.12	21	30851	3658	64464202
Cytomegalovirus enterocolitis	32.77	16.12	15	30857	1340	64466520
Insomnia	32.65	16.12	28	30844	197808	64270052
Liver abscess	32.56	16.12	24	30848	5256	64462604
Hypoaesthesia	32.39	16.12	13	30859	139095	64328765
Immune thrombocytopenia	32.38	16.12	38	30834	15028	64452832
Enterococcal bacteraemia	31.96	16.12	18	30854	2487	64465373
Blood culture positive	31.95	16.12	28	30844	7840	64460020
Blood bilirubin increased	31.82	16.12	79	30793	57474	64410386
Pulmonary haemorrhage	31.45	16.12	35	30837	13074	64454786
Rash morbilliform	30.87	16.12	23	30849	5118	64462742
Glomerulosclerosis	30.85	16.12	13	30859	952	64466908
Uraemic encephalopathy	30.82	16.12	11	30861	514	64467346
Botulism	30.76	16.12	10	30862	351	64467509
Feeling abnormal	30.28	16.12	13	30859	133589	64334271
Candida infection	30.10	16.12	54	30818	31365	64436495
Nausea	29.98	16.12	237	30635	785563	63682297
Renal impairment	29.90	16.12	136	30736	134881	64332979
Weight increased	29.71	16.12	35	30837	213313	64254547
Mixed liver injury	29.56	16.12	23	30849	5458	64462402
Arthritis	29.36	16.12	3	30869	83811	64384049
Enterococcal sepsis	29.35	16.12	17	30855	2477	64465383
Haemophagocytic lymphohistiocytosis	29.19	16.12	39	30833	17570	64450290
Pneumonia bacterial	29.17	16.12	36	30836	14999	64452861
Tumour lysis syndrome	29.13	16.12	41	30831	19399	64448461
Cytomegalovirus test positive	28.65	16.12	22	30850	5122	64462738
Acute myeloid leukaemia	28.64	16.12	49	30823	27414	64440446
Muscle spasms	28.51	16.12	16	30856	141007	64326853
Injection site pain	28.34	16.12	9	30863	111399	64356461
Hepatic function abnormal	28.19	16.12	81	30791	64232	64403628
Drug level increased	28.05	16.12	55	30817	34141	64433719
Off label use	27.88	16.12	441	30431	632365	63835495
Leukocytosis	27.75	16.12	58	30814	37682	64430178
Asthma	27.44	16.12	6	30866	95219	64372641
Disseminated mucormycosis	27.41	16.12	10	30862	498	64467362
Aspergillus infection	26.73	16.12	36	30836	16343	64451517
Staphylococcal infection	25.36	16.12	67	30805	50611	64417249
Lower respiratory tract infection	25.24	16.12	7	30865	94607	64373253
Nephritis allergic	25.04	16.12	10	30862	638	64467222
Sinusitis	24.88	16.12	20	30852	145908	64321952
Bacterial toxaemia	24.56	16.12	7	30865	156	64467704
Transaminases increased	24.42	16.12	61	30811	44533	64423327
Anxiety	24.40	16.12	37	30835	202612	64265248
Corynebacterium infection	24.25	16.12	11	30861	962	64466898
Activated partial thromboplastin time prolonged	23.74	16.12	30	30842	12801	64455059
Drug eruption	23.67	16.12	53	30819	36083	64431777
Graft versus host disease	23.52	16.12	31	30841	13782	64454078
Hypersensitivity	23.52	16.12	36	30836	196416	64271444
Enterobacter infection	23.24	16.12	17	30855	3679	64464181
Pseudomembranous colitis	23.04	16.12	19	30853	4897	64462963
Delirium	22.83	16.12	79	30793	69115	64398745
Burkholderia test positive	22.60	16.12	9	30863	570	64467290
Systemic mycosis	22.58	16.12	14	30858	2309	64465551
Klebsiella bacteraemia	22.48	16.12	14	30858	2326	64465534
Gastrooesophageal reflux disease	22.46	16.12	6	30866	83137	64384723
Paraesthesia	22.23	16.12	19	30853	134503	64333357
Blood urea increased	21.71	16.12	58	30814	44095	64423765
Procalcitonin increased	21.68	16.12	14	30858	2477	64465383
Discomfort	21.54	16.12	6	30866	80872	64386988
Swelling	21.54	16.12	27	30845	160191	64307669
Contusion	21.54	16.12	14	30858	113951	64353909
Lung infiltration	21.42	16.12	37	30835	20852	64447008
Vanishing bile duct syndrome	21.41	16.12	11	30861	1266	64466594
Asthenia	21.35	16.12	119	30753	427925	64039935
Back pain	21.25	16.12	56	30816	250115	64217745
Cerebral aspergillosis	21.16	16.12	12	30860	1681	64466179
Pulseless electrical activity	20.79	16.12	28	30844	12711	64455149
Unresponsive to stimuli	20.68	16.12	62	30810	50331	64417529
Rash maculo-papular	20.39	16.12	59	30813	46967	64420893
Respiratory alkalosis	20.26	16.12	16	30856	3881	64463979
Leukopenia	20.23	16.12	99	30773	101143	64366717
Acidosis	20.22	16.12	33	30839	17762	64450098
Memory impairment	19.95	16.12	8	30864	85674	64382186
Mediastinitis	19.70	16.12	9	30863	800	64467060
Shock	19.58	16.12	51	30821	38189	64429671
Escherichia bacteraemia	19.51	16.12	18	30854	5385	64462475
Small intestinal obstruction	19.44	16.12	38	30834	23535	64444325
Choluria	19.36	16.12	7	30865	340	64467520
Serum ferritin increased	19.27	16.12	22	30850	8446	64459414
Chemotherapeutic drug level increased	19.26	16.12	7	30865	345	64467515
Chest pain	19.16	16.12	54	30818	235926	64231934
Death	19.09	16.12	144	30728	482561	63985299
Device related infection	19.04	16.12	44	30828	30582	64437278
Laryngeal inflammation	19.01	16.12	6	30866	191	64467669
Product contamination microbial	18.95	16.12	9	30863	874	64466986
Cytokine storm	18.91	16.12	9	30863	878	64466982
Vision blurred	18.61	16.12	10	30862	90306	64377554
Vertigo	18.53	16.12	3	30869	59008	64408852
Hyperbilirubinaemia	18.49	16.12	35	30837	21170	64446690
Systemic lupus erythematosus	18.48	16.12	7	30865	77605	64390255
Hypertensive heart disease	18.46	16.12	15	30857	3789	64464071
Flavobacterium infection	18.44	16.12	5	30867	92	64467768
Drug-induced liver injury	18.04	16.12	57	30815	47586	64420274
Dyspepsia	17.90	16.12	8	30864	80304	64387556
Blood lactate dehydrogenase increased	17.85	16.12	45	30827	33033	64434827
Mucosal inflammation	17.73	16.12	68	30804	62516	64405344
Acute lymphocytic leukaemia recurrent	17.71	16.12	15	30857	4011	64463849
Eye infection fungal	17.57	16.12	7	30865	444	64467416
Injection site erythema	17.51	16.12	6	30866	70794	64397066
Systemic inflammatory response syndrome	17.47	16.12	23	30849	10212	64457648
Dialysis	17.39	16.12	30	30842	16890	64450970
Ureaplasma infection	17.32	16.12	8	30864	730	64467130
Chest discomfort	17.30	16.12	18	30854	116088	64351772
Dry mouth	17.02	16.12	4	30868	60414	64407446
Sputum culture positive	16.98	16.12	13	30859	3013	64464847
Engraftment syndrome	16.98	16.12	9	30863	1104	64466756
Blastomycosis	16.95	16.12	7	30865	487	64467373
Kidney fibrosis	16.70	16.12	13	30859	3088	64464772
Abdominal pain upper	16.58	16.12	37	30835	174993	64292867
Tachypnoea	16.32	16.12	38	30834	26533	64441327
Venoocclusive liver disease	16.32	16.12	22	30850	9993	64457867
Osteoarthritis	16.32	16.12	5	30867	63331	64404529
Tonsillitis bacterial	16.26	16.12	5	30867	146	64467714
Lymphatic disorder	16.24	16.12	6	30866	310	64467550
Pneumonitis	16.18	16.12	57	30815	50308	64417552

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01DE01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Fourth-generation cephalosporins
ATC	J01RA06	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE COMBINATIONS OF ANTIBACTERIALS Combinations of antibacterials
FDA CS	M0003827	Cephalosporins
FDA EPC	N0000175488	Cephalosporin Antibacterial
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
CHEBI has role	CHEBI:36047	antibacterial drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Infection due to Pseudomonas aeruginosa	indication	11218009
Pneumonia due to Streptococcus	indication	34020007
Pneumonia due to Pseudomonas	indication	41381004
Bacterial pneumonia	indication	53084003	DOID:874
Klebsiella cystitis	indication	60867007
Infectious disease of abdomen	indication	128070006
Bacterial infection due to Klebsiella pneumoniae	indication	186435004
Bacterial peritonitis	indication	197171003
Pneumococcal pneumonia	indication	233607000
Escherichia coli urinary tract infection	indication	301011002
Proteus urinary tract infection	indication	301012009
Streptococcus pyogenes infection	indication	302809008
Bacterial urinary infection	indication	312124009
Infection due to Staphylococcus aureus	indication	406602003
Urinary tract infection caused by Klebsiella	indication	369001000119100
Complicated Proteus UTI	indication
E. Coli Pyelonephritis	indication
Complicated Urinary Tract Infections	indication
Complicated Bacteroides Peritonitis	indication
Complicated Streptococcus Peritonitis	indication
Klebsiella Pyelonephritis	indication
Complicated E. Coli Peritonitis	indication
Enterobacter Pneumonia	indication
Complicated Klebsiella Peritonitis	indication
Proteus Pyelonephritis	indication
Myoclonus	contraindication	17450006
Colitis	contraindication	64226004	DOID:0060180
Blood coagulation disorder	contraindication	64779008	DOID:1247
Factor II deficiency	contraindication	73975000
Disorder of brain	contraindication	81308009	DOID:936
Seizure disorder	contraindication	128613002
Impaired renal function disorder	contraindication	197663003
Pseudomembranous enterocolitis	contraindication	397683000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.32	acidic
pKa2	13.31	acidic
pKa3	3.1	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Bacterial penicillin-binding protein	Enzyme		PBPA_ECOLI PBPB_ECOLI DACC_ECOLI PBP2_ECOLI FTSI_ECOLI DACA_ECOLI DACB_ECOLI	INHIBITOR				CHEMBL	CHEMBL

External reference:

ID	Source
4024049	VUID
N0000022054	NUI
D01157	KEGG_DRUG
123171-59-5	SECONDARY_CAS_RN
20481	RXNORM
4020908	VANDF
4024049	VANDF
C0055003	UMLSCUI
CHEBI:478164	CHEBI
9WT	PDB_CHEM_ID
CHEMBL186	ChEMBL_ID
CHEMBL1200962	ChEMBL_ID
D000077723	MESH_DESCRIPTOR_UI
DB01413	DRUGBANK_ID
10772	IUPHAR_LIGAND_ID
6092	INN_ID
807PW4VQE3	UNII
5479537	PUBCHEM_CID
116681	MMSL
4373	MMSL
d03882	MMSL
004974	NDDF
004975	NDDF
370370003	SNOMEDCT_US
370371004	SNOMEDCT_US
96048006	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
CEFEPIME HYDROCHLORIDE AND DEXTROSE	HUMAN PRESCRIPTION DRUG LABEL	1	0264-3193	INJECTION, SOLUTION	1 g	INTRAVENOUS	NDA	30 sections
CEFEPIME HYDROCHLORIDE AND DEXTROSE	HUMAN PRESCRIPTION DRUG LABEL	1	0264-3193	INJECTION, SOLUTION	1 g	INTRAVENOUS	NDA	30 sections
CEFEPIME HYDROCHLORIDE AND DEXTROSE	HUMAN PRESCRIPTION DRUG LABEL	1	0264-3195	INJECTION, SOLUTION	2 g	INTRAVENOUS	NDA	30 sections
CEFEPIME HYDROCHLORIDE AND DEXTROSE	HUMAN PRESCRIPTION DRUG LABEL	1	0264-3195	INJECTION, SOLUTION	2 g	INTRAVENOUS	NDA	30 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1301	INJECTION, SOLUTION	1 g	INTRAVENOUS	NDA	28 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1301	INJECTION, SOLUTION	1 g	INTRAVENOUS	NDA	28 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	0409-9566	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	27 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	0409-9735	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	27 sections
Cefepime Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3222	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	27 sections
Cefepime Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3223	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	27 sections
cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	25021-121	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	29 sections
cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	25021-121	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	29 sections
cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	25021-122	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	29 sections
cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	25021-122	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	29 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	44567-130	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	26 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	44567-131	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	26 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	44567-240	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	26 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	44567-241	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	26 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6144	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	28 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6144	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	28 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6145	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	28 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6145	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	28 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6146	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	28 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6146	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	28 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6147	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	28 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6147	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	28 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	63323-326	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAVENOUS	ANDA	27 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	63323-340	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	27 sections
CEFEPIME	HUMAN PRESCRIPTION DRUG LABEL	1	66288-8100	INJECTION, POWDER, FOR SOLUTION	100 g	INTRAVENOUS	ANDA	18 sections
Cefepime	HUMAN PRESCRIPTION DRUG LABEL	1	66794-209	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	17 sections